Social•Apr 17, 2026
Ribupatide Must Shine; Late GLP‑1 Faces Market Hurdles
All I'm going to say is that ribupatide needs to be a helluva drug for any of this to make sense. A me-too GLP-1 coming in a decade late seems like a big commercial challenge. $KLRA https://t.co/MAmA5f6FZ8
By Jon Gardner
Social•Apr 7, 2026
Enjoying 14D‑9s to Identify Companies A, B, C
I'm sure this is a favorite thing for other people to do, but I love reading 14D-9s and guessing which company Party A, B, or C is based on their behavior. $TERN $MRK
By Jon Gardner
Social•Mar 27, 2026
AstraZeneca Honors Faerie Royalty in COPD Trial Names
Hats off to $AZN for naming its COPD trials after the king and queen of the faeries.
By Jon Gardner
Social•Mar 20, 2026
FDA Finally Holds Public Hearing on Priority Review Vouchers
Oh, *now* the FDA has decided to have a public hearing on the national priority review voucher program. After four drugs have completed the process. A year after the program was announced. This must be that "radical transparency" that @DrMakaryFDA...
By Jon Gardner